There’s a particular kind of tension that emerges when a company’s management and its most vocal critics are looking at the same stock and drawing opposite conclusions. Novo Nordisk is living that tension right now, in plain sight of the market.
Since the start of February, the Danish pharmaceutical giant has been steadily accumulating its own B-shares. Through August 21, the company had repurchased nearly 30 million shares at an average price of 280.34 Danish kroner, representing a transaction volume exceeding 8.3 billion kroner. A week later, the tally had inched past that mark to roughly 8.4 billion kroner, with more than a million additional shares bought in a single trading week alone.
The buyback is methodical, consistent, and expensive. Whether it is effective is another matter entirely.
A Stock That Keeps Sliding
The share price tells a sobering story. At last check, the stock traded at 39.06 euros, down 0.9 percent on the day. Over twelve months, the decline stands at 21 percent, and the shares now sit 29 percent below their January 52-week high. A closing price of 39.41 euros on the most recent Friday puts the stock roughly 28 percent beneath that same peak, with the week’s move a modest 2.0 percent decline.
The technical picture reinforces the fundamental unease. The shares trade about 6.5 percent below their 50-day average and hover just under the 200-day average — a chart pattern that mirrors the broader uncertainty surrounding the company’s growth trajectory.
Two Banks, Two Verdicts
The analyst community is split in a way that underscores just how contested Novo Nordisk’s outlook has become. On August 27, Deutsche Bank downgraded the stock to Sell and cut its price target by 9 percent to 265 kroner. Analyst Emmanuel Papadakis cited trimmed medium-term revenue estimates following the failure of the Ziltivekimab trial — the drug candidate did not reduce heart attack or stroke risk in a late-stage cardiovascular study.
Two days earlier, JPMorgan moved in the opposite direction, lifting its price target from 250 to 275 kroner while maintaining a Neutral rating. The rationale: higher revenue expectations for Ozempic, driven by less severe generic erosion in the U.S. market than feared and favorable gross-to-net adjustments.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Two institutions, nearly simultaneous, drawing opposite conclusions from the same set of facts. That divergence is itself a signal — the market simply does not agree on what Novo Nordisk is worth.
China’s Door Opens
Amid the clinical setbacks, the company is pressing forward on other fronts. On August 27, China’s National Medical Products Administration accepted Novo Nordisk’s application for an oral version of Wegovy. The Chinese market pits Novo Nordisk directly against Eli Lilly, and an approved pill formulation could offer a structural advantage — assuming regulatory approval ultimately materializes.
The company is also advancing the pill’s clinical development. A late-stage study launched August 12 will test lower doses of the Wegovy tablet across 450 participants at 62 sites in the U.S. and Europe, aiming to identify the lowest effective maintenance dose. That effort could improve both tolerability and cost-efficiency over the long run.
Partnerships and Milestones
The collaboration front has been active as well. Lexicon Pharmaceuticals received a third milestone payment of $10 million from Novo Nordisk under their joint obesity program — a sign of progress in the pipeline, though specifics on the development step were not disclosed.
Earlier in August, Novo Nordisk announced a strategic partnership with Amazon Web Services, establishing a joint innovation center in London to accelerate drug development using agentic AI and cloud technology. The goal is to compress the timeline from target identification to first human application. This is a bet on the next decade, not a near-term catalyst.
The Unresolved Equation
The core question remains whether roughly 8.3 billion kroner in buybacks can restore confidence that clinical reality is actively undermining. Buybacks signal management’s conviction in intrinsic value, but they do not substitute for a functioning pipeline. As long as setbacks like Ziltivekimab weigh on medium-term estimates, the arithmetic of trust stays stubbornly unresolved.
For investors, the picture is a mosaic of competing signals: positive regulatory momentum in China, advancing clinical studies, a skeptical sell rating from one major bank, and a management team spending billions to demonstrate its own belief in the stock. The market’s verdict, so far, is that none of it is quite enough.
Ad
Novo Nordisk Stock: Buy or Sell?! New Novo Nordisk Analysis from August 31 delivers the answer:
The latest Novo Nordisk figures speak for themselves: Urgent action needed for Novo Nordisk investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from August 31.
Novo Nordisk: Buy or sell? Read more here...
